Education
About Us
Working with TipRanks
Follow Us
Yunkang Group Limited (HK:2325)
:2325
2325 Stock Chart & Stats
HK$0.99
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.99
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.65 - HK$4.98
Previous CloseN/A
Volume10.00K
Average Volume (3M)1.61M
Market Cap
HK$559.13M
Enterprise Value-HK$213.54M
Total Cash (Recent Filing)HK$1.69B
Total Debt (Recent Filing)HK$1.02B
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)-1.21
Shares Outstanding621,250,500
10 Day Avg. Volume4,171,850
30 Day Avg. Volume1,613,200
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.52
Price to Sales (P/S)7.26
P/FCF Ratio22.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$884.18M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageA moderate debt-to-equity ratio provides financial flexibility over the medium term, lowering default risk and giving management room to allocate cash toward operations, R&D, or restructuring. This durable capital structure helps sustain operations through cyclical revenue pressure and supports strategic investments.
Positive Free Cash FlowPositive free cash flow indicates the business is generating cash from core operations even amid revenue declines. That cash generation supports debt servicing, working capital needs, and selective investment, giving the company more runway to execute turnarounds or preserve liquidity without immediate capital raises.
Defensive Industry ExposureOperating in diagnostics and medical research exposes the company to structurally steady healthcare demand and regulatory-driven barriers to entry. These industry characteristics can support recurring revenue streams, long product lifecycles and customer stickiness, benefiting fundamentals over multiple quarters.
Bears Say
Declining Revenues & Negative MarginsSustained revenue decline and contracting gross and net margins undermine long-term profitability and operational scalability. Negative EBIT/EBITDA margins signal structural cost or pricing issues that require strategic fixes; without revenue stabilization, margins may remain pressured and cash generation could deteriorate.
Weakened Equity BaseA falling shareholders' equity base reduces balance sheet resilience and increases vulnerability to shocks or external financing needs. Persistent equity erosion can limit strategic options, increase reliance on debt or dilutive equity issuance, and constrain capacity to absorb losses or invest for recovery.
Sharp Revenue And EPS ContractionDouble‑digit negative revenue growth and extreme EPS contraction indicate rapid earnings deterioration that can persist absent clear operational fixes. Such structural declines impair reinvestment capability, weaken stakeholder confidence, and make multi-quarter recovery more challenging without meaningful strategic or product changes.
Yunkang Group Limited News
2325 FAQ
What was Yunkang Group Limited’s price range in the past 12 months?
Yunkang Group Limited lowest stock price was HK$0.65 and its highest was HK$4.98 in the past 12 months.
What is Yunkang Group Limited’s market cap?
Yunkang Group Limited’s market cap is HK$559.13M.
When is Yunkang Group Limited’s upcoming earnings report date?
Yunkang Group Limited’s upcoming earnings report date is Mar 30, 2026 which is in 10 days.
How were Yunkang Group Limited’s earnings last quarter?
Yunkang Group Limited released its earnings results on Mar 28, 2025. The company reported -HK$1.214 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$1.214.
Is Yunkang Group Limited overvalued?
According to Wall Street analysts Yunkang Group Limited’s price is currently Overvalued.
Does Yunkang Group Limited pay dividends?
Yunkang Group Limited pays a Annually dividend of HK$0.02 which represents an annual dividend yield of 2.15%. See more information on Yunkang Group Limited dividends here
What is Yunkang Group Limited’s EPS estimate?
Yunkang Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yunkang Group Limited have?
Yunkang Group Limited has 621,250,500 shares outstanding.
What happened to Yunkang Group Limited’s price movement after its last earnings report?
Yunkang Group Limited reported an EPS of -HK$1.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Yunkang Group Limited?
Currently, no hedge funds are holding shares in HK:2325
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yunkang Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.62%
12-Months-Change
Fundamentals
Return on Equity
-47.91%
Trailing 12-Months
Asset Growth
-23.34%
Trailing 12-Months
Company Description
Yunkang Group Limited
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction and screening tests; and routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. In addition, the company offers diagnostic testing services for financial institutions and insurance companies, including personalized diagnostic testing, medical report consultation, and hospital referral services; information technology, medical logistics, and medical equipment procurement; healthcare technology development; and project investment. It provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
Technical Analysis
MicroPort CardioFlow Medtech Corp.
―
Beijing Airdoc Technology Co. Ltd. Class H
―
C-MER Eye Care Holdings Limited
―
Mega Genomics Limited
―